[ad_1]
Eli Lilly & Co.’s stock jumped 8% premarket Wednesday, after the company LLY announced positive results from a late-stage trial of its Alzheimer’s disease treatment donanemab.
The Phase 3 trial showed that donanemab “significantly slowed cognitive and functional decline” in patients with early symptomatic Alzheimer’s disease, and met its primary and all secondary endpoints, or goals.
Nearly…
[ad_2]
Source link
